Inovio Pharmaceuticals

INO

Market cap $142M

PLYMOUTH MEETING, Pa. , Nov. 18, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer and infectious diseases, today announced that it will participate in the following investor conferences: Piper Sandler 37th Annual Healthcare Conference (New York, NY) Date: Tuesday, December 2 Time: 8:30-8:55 AM ET Format: Fireside Chat Webcast:  https://bit.ly/44af19l (live webcast and replay available for 90 days after the event) Oppenheimer Movers in Rare Disease Summit (New York, NY) Date: Thursday, December 11 Time: 12:05-12:25 PM ET Format: Panel - Elevator Pitches from Rare Disease Companies with Key Near-Term, Potentially Stock-Moving Catalysts Members of INOVIO's management team will also be conducting one-on-one meetings with investors during these conferences.

Inovio (INO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Inovio Pharmaceuticals (INO) reported a disappointing 3Q25 with a GAAP EPS loss of -$0.87, missing consensus by $0.45 and triggering a 12% stock slide. INO ended the quarter with $50.8 million in cash, expects a runway into 2Q26, and announced a $25 million public offering to support operations. Key pipeline progress includes completion of the BLA submission for INO-3107, with hopes for FDA priority review and potential U.S. launch by mid-2026.

PLYMOUTH MEETING, Pa. , Nov. 11, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced the pricing of an underwritten public offering of 13,158,000 shares of its common stock at a public offering price of $1.90 per share.

Inovio Pharmaceuticals, Inc. ( INO ) Q3 2025 Earnings Call November 10, 2025 4:30 PM EST Company Participants Jennie Willson Jacqueline Shea - CEO, President & Director Michael Sumner - Chief Medical Officer Steven Egge - Chief Commercial Officer Peter Kies - Chief Financial Officer Conference Call Participants Edward Tenthoff - Piper Sandler & Co., Research Division Jay Olson - Oppenheimer & Co. Inc., Research Division Felix Ampomah Eduardo Martinez-Montes - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good afternoon, ladies and gentlemen, and welcome to the Inovio Third Quarter 2025 Financial Results Conference Call.

PLYMOUTH MEETING, Pa. , Nov. 10, 2025 /PRNewswire/ -- INOVIO Pharmaceuticals, Inc. (Nasdaq: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.

Completed rolling Biologics License Application (BLA) submission seeking accelerated approval for lead candidate INO-3107; requested priority review Expect to receive file acceptance by year end 2025 with potential PDUFA date in mid-2026 if request for priority review granted Commercial preparations continuing for potential launch in mid-2026 if INO-3107 is approved by FDA Results from Phase 1 proof-of-concept trial evaluating INOVIO's next generation DNA-Encoded Monoclonal Antibody (DMAb™) technology published in Nature Medicine PLYMOUTH MEETING, Pa. , Nov. 10, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the third quarter of 2025 and provided an update on recent company developments.

Recurrent respiratory papillomatosis (RRP) is a rare HPV-related disease of the respiratory tract with significant unmet need INO-3107 previously received Orphan Drug and Breakthrough Therapy designations; BLA submitted under FDA's Accelerated Approval program Expect to receive file acceptance by year end 2025 with potential PDUFA date in mid-2026 if request for priority review granted PLYMOUTH MEETING, Pa. , Nov. 3, 2025 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has completed the rolling submission of its Biologics License Application (BLA) for its DNA immunotherapy candidate INO-3107 for the treatment of RRP in adults.

PLYMOUTH MEETING, Pa. , Oct. 31, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").

PLYMOUTH MEETING, Pa. , Oct. 27, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancers, and infectious diseases, today announced that its third quarter 2025 financial results will be released after the market close on November 10, 2025.